| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Giorgio Valabrega | Q57374820 |
| Massimo Aglietta | Q60538695 | ||
| P2093 | author name string | Sofia Genta | |
| Gloria Mittica | |||
| P2860 | cites work | Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 |
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer | Q24685406 | ||
| Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives | Q26749280 | ||
| Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma | Q27853285 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Q28202471 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| PD-L1 regulates the development, maintenance, and function of induced regulatory T cells | Q30080038 | ||
| Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group | Q33393033 | ||
| Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer | Q62112715 | ||
| Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma | Q81318600 | ||
| Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study | Q81570219 | ||
| High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation | Q84014638 | ||
| Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial | Q87460208 | ||
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
| Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer | Q40241719 | ||
| B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression | Q40528021 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer | Q41386447 | ||
| Epigenetic Modulators and the New Immunotherapies | Q42699499 | ||
| A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study | Q44315213 | ||
| Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer | Q45072359 | ||
| Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer | Q46748103 | ||
| Adaptive immunity maintains occult cancer in an equilibrium state | Q46891052 | ||
| Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study | Q48401064 | ||
| The prognostic significance of PD-L1 in bladder cancer. | Q50978399 | ||
| BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. | Q53189566 | ||
| NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. | Q53257187 | ||
| PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. | Q53793413 | ||
| Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. | Q53965542 | ||
| VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. | Q54710399 | ||
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. | Q33421351 | ||
| Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study | Q33501657 | ||
| Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. | Q33799806 | ||
| Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival | Q34048270 | ||
| Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer | Q34210036 | ||
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. | Q34422265 | ||
| PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma | Q34577802 | ||
| Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. | Q34657786 | ||
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | Q34670965 | ||
| The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints | Q34943776 | ||
| Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients | Q34959906 | ||
| The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy | Q34970884 | ||
| The role of dendritic cell precursors in tumour vasculogenesis. | Q36078034 | ||
| B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. | Q36272357 | ||
| Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer | Q36405652 | ||
| Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. | Q36439488 | ||
| Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients | Q36498459 | ||
| Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy | Q36718954 | ||
| Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary | Q36733127 | ||
| OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 | ||
| Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials | Q36826591 | ||
| miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint | Q36875531 | ||
| Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer | Q37046405 | ||
| CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer | Q37173597 | ||
| Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine | Q37420192 | ||
| Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. | Q37718427 | ||
| Prognostic and predictive markers for the new immunotherapies. | Q38266704 | ||
| Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma | Q38393470 | ||
| Targeting the programmed cell death-1 pathway in breast and ovarian cancer | Q38735374 | ||
| Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer | Q38819171 | ||
| The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model | Q39010434 | ||
| Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer | Q39050794 | ||
| Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines | Q39511749 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell cycle checkpoint signaling | Q1068809 |
| immunotherapy | Q1427096 | ||
| ovarian neoplasm | Q11793790 | ||
| antineoplastic | Q2853144 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1169 | |
| P577 | publication date | 2016-07-20 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? | |
| P478 | volume | 17 |
| Q33608191 | A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. |
| Q38373221 | A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer |
| Q47861842 | A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer |
| Q42056165 | Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer |
| Q52582442 | An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides. |
| Q55164226 | Are ovarian cancer stem cells the target for innovative immunotherapy? |
| Q52715784 | BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer. |
| Q42323210 | Cancer Immunology with a Focus on Understudied Cancers as Targets for Immunotherapy |
| Q92359078 | Cauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread |
| Q37679904 | Clinical response in patients with ovarian cancer treated with metronomic chemotherapy |
| Q92524991 | Differential expression of immune related genes in high-grade ovarian serous carcinoma |
| Q91889112 | Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment |
| Q49885235 | Effect of ovarian cancer ascites on SKOV-3 cells proteome: new proteins associated with aggressive phenotype in epithelial ovarian cancer |
| Q99555926 | Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy |
| Q52721812 | Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma. |
| Q64075600 | Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6 |
| Q90569691 | Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade |
| Q37702688 | Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer |
| Q89184189 | Metastatic gynecologic malignancies: advances in treatment and management |
| Q28066904 | Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment |
| Q92816136 | Ovarian Cancer Immunotherapy: Turning up the Heat |
| Q92512914 | Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report |
| Q47201278 | Reprogramming T-cells for adoptive immunotherapy of ovarian cancer |
| Q58766967 | Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma |
| Q37620902 | TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer |
| Q52730115 | Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). |
| Q47685928 | Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients |
| Q98771756 | Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy |
Search more.